secwatch.observer — SEC 8-K summary
======================================

Issuer:     Karyopharm Therapeutics Inc. (KPTI)
CIK:        0001503802
Form:       8-K
Filed at:   2023-05-04T23:59:59+00:00
Accession:  0001193125-23-135082
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Karyopharm cuts FY2023 revenue guidance on higher patient assistance; Q1 net loss narrows
--------------------------------------------------------------------------------

- Q1 total revenue $38.7M, XPOVIO net product revenue $28.3M flat YoY; net loss $34.1M ($0.30/sh) vs $41.4M loss YoY.
- FY2023 total revenue guidance lowered to $145-160M (from $160-175M); XPOVIO net product revenue now $110-125M due to increased patient assistance programs.
- Non-GAAP R&D and SG&A expense guidance reduced to $245-260M; cash runway reiterated to late 2025.
- Phase 1 selinexor+ruxolitinib in front-line MF: 83.3% SVR35 at wk12, 80% TSS50; Phase 3 planned 1H 2023.
- Eltanexor in Hr R/R MDS interim: median OS 8.7 months; UK marketing authorization granted for NEXPOVIO combo.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1503802/000119312523135082/0001193125-23-135082-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1503802/000119312523135082/d236538d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-135082

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer